Major US Advisory Committee to Vote on Changing Baby Hepatitis B Vaccine Recommendation
Following a postponement and a remarkably divisive gathering, a national immunization advisory committee was expected to vote on Friday on whether to change the enduring advisory that all newborns be inoculated against hepatitis B.
Heated Debate and a Postponed Decision
The initial day of the conference on Thursday was marked by heated debate over restricting access to the hepatitis B vaccine for infants and a choice to postpone the decision by a day to provide committee members extra time to examine the language. The committee, which advises the Centers for Disease Control and Prevention on vaccination protocols, had put off the vote twice in the past.
“Is there any specific evidence of damage of giving this shot before 30 days? Or is this theory?” asked one adviser.
In response, another participant stated, “There is inadequate data about the prolonged hazard.”
Current Guidelines and Likely Ramifications
The shot is presently advised for all infants within 24 hours of being born to prevent infection of hepatitis B, which can result in significant hepatic injury. It has been given to 1.4 billion people for in excess of thirty years.
The Georgia assembly offered no fresh data of damage attributable to the vaccine. Experts say any alteration to the current hepatitis B immunization timeline could have major and extensive implications for childhood health in the United States.
Panel Composition and New Appointments
The advisory panel can only offer guidance to the director of the CDC. The committee's composition has seen shifts in recent days, with the announcement that the committee’s most recent chair would leave for an official role and be substituted with a cardiologist who has been critical of other immunizations.
The panel includes a number of vaccination critics who align with a aim to revamp – and potentially, in some cases, eliminate – long-established vaccination recommendations.
